CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced it will present nine company-sponsored abstracts at the 62^nd American Society of Hematology (ASH) Annual Meeting, being held virtually for the first time December 5-8, 2020. These data span Takeda’s extensive hematology portfolio and R&D pipeline, featuring results across various bleeding disorders, including hemophilia A, von Willebrand disease and sickle cell disease. The Takeda Hematology team is proud to once again have a significant presence at ASH along with Takeda Oncology, which shared its abstracts in a separate release.

These data contribute to a greater understanding of bleeding disorders and Takeda’s hematology portfolio, and highlights Takeda’s commitment to advancing personalized care approaches for patients with bleeding disorders.

“Rare bleeding disorder patients need consistent, personalized treatment approaches and support. This unprecedented year has stressed the importance of creating solutions tailored to the individual patient and their unique needs,” Cheryl Schwartz, Senior Vice President, head of Takeda’s U.S. Rare Disease Business Unit, said. “We are proud that the data being presented at this year’s ASH meeting underscore our commitment to the rare bleeding disorders community.”

A full list of accepted hematology abstracts is outlined below. All times listed are in Pacific Standard Time:

Bleeding Disorder/Disease State		Abstract Title		Abstract Number/Presentation Details
Hemophilia A		Patient Preferences for Hemophilia A Treatments: A Discrete Choice Experiment		Day: December 5, 2020 Time: Poster Hall (Virtual Meeting) 7:00 AM-3:30 PM #1623 poster presentation Session #904
		Effectiveness and Safety Outcomes in Patients with Hemophilia A Receiving Antihemophilic Factor (Recombinant) for At Least 5 Years in a Real-world Setting: 6-Year Interim Analysis of the AHEAD International and German Studies		Day: December 7, 2020 Time: Poster Hall (Virtual Meeting) 7:00 AM-3:30 PM #2698 poster presentation Session #322
		Dosing, Patient Satisfaction and Other Patient-Reported Outcomes after Switching to Rurioctocog Alfa Pegol in ATHN 2: A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Coagulation Replacement Factor Products		Day: December 5, 2020 Time: Poster Hall (Virtual Meeting) 7:00 AM-3:30 PM #870 poster presentation Session #322
		Assessing Patient Experiences with Prophylactic Treatments for Hemophilia A: Concept Elicitation for Gene Therapy		Blood Volume 136, Issue Supplement 1 November 5, 2020 Online publish only
von Willebrand Disease		Characterization of Hysterectomy in Women with VWD Using Data from a US Medical Claims Database		Day: December 6, 2020 Time: Poster Hall (Virtual Meeting) 7:00 AM-3:30 PM #1794 poster presentation Session #322
		Assessment of rVWF Pharmacokinetics in Overweight and Obese VWD Patients Using a Population Pharmacokinetic Model		Day: December 5, 2020 Time: Poster Hall (Virtual Meeting) 7:00 AM-3:30 PM #859 poster presentation Session #322
		Retrospective Chart Review of Gastrointestinal Bleeding in Patients With von Willebrand Disease		Blood Volume 136, Issue Supplement 1 November 5, 2020 Online publish only
Congenital Hemophilia A or Hemophilia B		Real-world clinical management of patients with congenital hemophilia and inhibitors: interim analysis of the FEIBA Global Outcome study (FEIBA GO)		Blood Volume 136, Issue Supplement 1 November 5, 2020 Online publish only
Sickle Cell Disease		Prevalence of Vasco-occlusive Crises (VOCs) in Patients with Sickle Cell Disease: A Retrospective US Claims Database Analysis		Blood Volume 136, Issue Supplement 1 November 5, 2020 Online publish only

About Hemophilia
Hemophilia is a chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood.¹ Hemophilia A is more common than hemophilia B; in 2018, hemophilia A affects about 158,225 people, whereas hemophilia B affects about 31,247 people worldwide.² People with hemophilia, working closely with their healthcare professionals, can live healthy lives with proper care and adequate treatment. Treatment regimens typically include on-demand and/or regular prophylactic infusions of factor replacement therapy to control or prevent the risk of bleeding.^1,2

About von Willebrand disease (VWD)
VWD is the most common inherited bleeding disorder, affecting up to one percent of the U.S. population.³ VWD is caused by a deficiency or dysfunction of von Willebrand factor (VWF), one of several types of proteins in the blood that are needed to facilitate proper blood clotting.³ Due to this defect or deficiency in VWF, blood is not able to clot effectively in people with VWD, which may result in heavy menstrual periods, easy bruising or frequent nose bleeds.³ Bleeding caused by VWD varies greatly among patients with this disease.⁴

About Takeda Hematology
Takeda is a leader in hemophilia with the longest heritage and a market-leading portfolio, backed by established safety and efficacy profiles with decades of real-world experience. We have 70+ years of experience driving innovation for patients and a broad portfolio of 11 products across multiple bleeding disorders.⁹ Our experience as leaders in hematology means we are well prepared to meet today’s needs as we pursue future developments in the treatment of bleeding disorders. Together with the hematology community, we are committed to raising expectations for the future, including earlier diagnosis, earlier and better protection against bleeds, and more personalized patient care.

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit https://www.takeda.com.

References

1. World Federation of Hemophilia. Introduction to hemophilia: what is hemophilia?. World Federation of Hemophilia website. Available at: https://elearning.wfh.org/elearning-centres/introduction-to-hemophilia/#what_is_hemophilia. Last accessed October 2020.
2. World Federation of Hemophilia. Report on the Annual Global Survey 2018. World Federation of Hemophilia website. http://www1.wfh.org/publications/files/pdf-1731.pdf. Last accessed October 2020.
3. National Hemophilia Foundation. "Von Willebrand Disease." National Hemophilia Foundation website. https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Von-Willebrand-Disease. Last accessed October 2020.
4. “Rare Diseases.” Takeda Website. https://www.takeda.com/what-we-do/areas-of-focus/rare-diseases/. Last accessed October 2020.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takeda’s estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s), any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key Information—D. Risk Factors” in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005345/en/